Please use this identifier to cite or link to this item:
Title: Benefit-risk assessment of orlistat in the treatment of obesity.
Authors: Sumithran, Priya;Proietto, Joseph
Affiliation: Department of Medicine (Austin Health), University of Melbourne, Heidelberg Repatriation Hospital, Heidelberg, VIC, 3081, Australia,
Issue Date: 1-Aug-2014
Citation: Drug Safety; 37(8): 597-608
Abstract: Orlistat, an inhibitor of intestinal lipase, has been available for the treatment of obesity for nearly two decades. In conjunction with a hypocaloric diet, orlistat treatment results in a placebo-subtracted reduction in body weight of around 3 kg at 1 year, and increases the likelihood of achieving clinically significant (≥5%) weight loss by around 20%. Orlistat-induced weight loss also confers modest improvements in systolic and diastolic blood pressure, low-density lipoprotein (LDL) cholesterol, glycemic parameters, and progression to diabetes in people with impaired glucose tolerance. Overall, it has a good safety profile, and serious adverse events (including reports of severe kidney and liver injury) are rare. However, a high rate of gastrointestinal side effects limits adherence to treatment.
Internal ID Number: 25064699
DOI: 10.1007/s40264-014-0210-7
Type: Journal Article
Subjects: Anti-Obesity Agents.adverse effects.pharmacology.therapeutic use
Body Weight.drug effects
Gastrointestinal Diseases.chemically induced
Lactones.adverse effects.pharmacology.therapeutic use
Medication Adherence
Obesity.drug therapy
Risk Assessment
Appears in Collections:Journal articles

Files in This Item:
File SizeFormat 
25064699.pdf70.52 kBAdobe PDFView/Open

Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.